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Abstract 
The apelinergic system is an important player in the regulation of both vascular tone and 
cardiovascular function, making this physiological system an attractive target for drug 
development for hypertension, heart failure and ischemic heart disease. Indeed, apelin exerts a 
positive inotropic effect in humans whilst reducing peripheral vascular resistance. In this study, 
we investigated the signaling pathways through which apelin exerts its hypotensive action. We 
synthesized a series of apelin-13 analogs whereby the C-terminal Phe13 residue was replaced by 
natural or unnatural amino acids. In HEK293 cells expressing APJ, we evaluated the relative 
efficacy of these compounds to activate Gαi1 and GαoA G-proteins, recruit β-arrestins 1 and 2 
(βarrs), and inhibit cAMP production. Calculating the transduction ratio for each pathway allowed 
us to identify several analogs with distinct signaling profiles. Furthermore, we found that these 
analogs delivered i.v. to Sprague-Dawley rats exerted a wide range of hypotensive responses. 
Indeed, two compounds lost their ability to lower blood pressure, while other analogs significantly 
reduced blood pressure as apelin-13. Interestingly, analogs that did not lower blood pressure were 
less effective at recruiting βarrs. Finally, using Spearman correlations, we established that the 
hypotensive response was significantly correlated with βarr recruitment but not with G protein-
dependent signaling. In conclusion, our results demonstrated that the βarr recruitment potency is 
involved in the hypotensive efficacy of activated APJ. 
 
Keywords: G Protein-Coupled Receptor (GPCR); G Protein; β-arrestin; Apelin receptor; 
Hypotension; Blood Pressure 
Chemical compounds studied in this article: [Pyr1]-apelin-13 (PubChem CID: 25085173)  
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1. Introduction 
The apelin receptor (angiotensin receptor-like 1, APJ) is a seven transmembrane receptor (7TMR) 
that belongs to the class A peptidergic G protein-coupled receptors (GPCR) superfamily [1]. The 
endogenous ligands of APJ are the different isoforms of apelin (namely apelin-13, -17, and -36) 
[2] as well as the recently discovered ELABELA/Toddler [3]. The apelinergic axis is known to be 
widely distributed throughout the body, both in the central nervous system and at the periphery 
[4,5]. Peripherally, components of the apelin/APJ system are mainly expressed in the lungs, 
kidneys, pancreas as well as in the cardiovascular system [6]. Recently, the apelinergic system has 
been highlighted as a potential and promising target for drug development [7]. Indeed, modulating 
APJ signaling can be considered for the treatment of diabetes, obesity, cancer, and HIV infection 
[4]. However, the most important role of the apelin-APJ axis remains associated to its 
cardiovascular actions. Indeed, apelin peptides act as potent regulators of vascular function and 
exert one of the most powerful positive inotropic actions [8]. Accordingly, the apelin-APJ axis is 
widely distributed within the cardiovascular system, being expressed on endothelial cells, vascular 
smooth muscle cells and cardiomyocytes [9]. In preclinical models, APJ activation induces a 
significant drop in mean arterial blood pressure (MABP), reduces ventricular preload and 
afterload, increases myocardial contractility, and decreases angiotensin II-induced myocardial 
hypertrophy and fibrosis (for review see [10,11]). In rodents, the hypotensive actions of apelin-13 
and apelin-17 are blocked by a pretreatment with L-NAME, a nitric oxide (NO) synthase inhibitor 
[12]. These beneficial/protective effects of apelin are paralleled in healthy volunteers and in 
chronic heart failure patients, in whom an intravenous (i.v.) injection of apelin-13 induces a 
vasodilation of coronary and peripheral blood vessels leading to a lowering of MABP, while 
increasing the cardiac output [13,14]. In support of the role of the apelin/APJ system in 
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cardiovascular function and pathology, plasma levels of apelin are markedly decreased in patients 
with chronic heart failure and failing human hearts also exhibit altered apelin and APJ gene 
expression patterns [15,16]. 
At the cellular level, activation of APJ triggers several intracellular signaling pathways such as the 
activation of the Gαi/o pathway leading to inhibition of adenylate cyclase and a lowering of cAMP 
production [5]. Apelin-13 binding to APJ also induces the phosphorylation of the mitogen-
activated protein kinase (MAPK) ERK1/2 by a Gαi/o-dependent mechanism since this effect is 
blocked by a pretreatment with pertussis toxin (PTX) [17]. APJ activation further induces the 
recruitment of both β-arrestins 1 and 2 (βarrs), leading to receptor internalization [18,19]. 
Interestingly, intracellular trafficking routes seem to be agonist-dependent with, on the one hand, 
apelin-13 and -17, which induce a transient interaction between APJ and βarr, and on the other 
hand, apelin-36, which displays a long lasting APJ/βarr interaction [20]. 
Structure-activity relationship (SAR) and alanine-scan have highlighted that the N-terminal amino 
acids of apelin-13 (i.e. Arg2-Pro3-Arg4-Leu5) are involved in binding to APJ and activation of the 
Gαi/o signaling pathway [5]. However, the C-terminal of apelin plays a crucial role in modulating 
APJ internalization and βarr recruitment as well as being responsible for the APJ-dependent 
hypotensive response [18,21]. Indeed, the truncation of the C-terminal Phe residue or its 
replacement by Ala in apelin-13 or apelin-17 results in an impairment of the MABP lowering 
effect of these compounds [22]. Accordingly, we recently published that the substitution of Phe13 
by unnatural amino acids induces changes in cAMP production and also affects the hypotensive 
action of these C-terminal modified apelin-13 analogs [19]. Herein, we examined the APJ 
signaling profile of a series of C-terminal modified analogs by studying their ability to activate 
Gαi1, GαoA, inhibit cAMP production, and recruit βarrs. We further monitored the potency of these 
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compounds to elicit changes in MABP in rodents. To pair APJ receptor activity with its 
physiological effects, we finally applied the Black and Leff operational model to correlate the drop 
in MABP with a specific signaling signature.  
  
This is the accepted (postprint) version of the following article: Besserer-Offroy É, et al. (2018), 
Pharmacol Res. doi: 10.1016/j.phrs.2018.02.032, which has been accepted and published in its 
final form at https://www.sciencedirect.com/science/article/pii/S1043661817313804 
 
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 
license http://creativecommons.org/licenses/by-nc-nd/4.0/  
 8 
2. Materials and methods 
2.1. Materials 
All compounds including apelin-13 were synthesized by us as previously described [19]. 
Coelenterazine 400A (DeepBlueC) was purchased from Gold Biotechnology Inc. (St. Louis, MO, 
USA). DMEM, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), Penicillin-
streptomycin-glutamine and fetal bovine serum (FBS) were obtained from Wisent (St. Bruno, QC, 
Canada), Opti-MEM was acquired from Invitrogen (Burlington, ON, Canada). Lance Ultra cAMP 
assay kit was purchased from Perkin Elmer (Montréal, QC, Canada). 
2.2. Plasmids and constructs 
Using an InFusion advantage PCR cloning kit (Clontech Laboratories, Mountain View, CA, USA), 
the hAPJ construct was inserted into the pIREShygro3-GFP10 vector as previously described [18]. 
The plasmids encoding RlucII-β-arrestin 1 or 2 [23], GαoA-RlucII [24], Gαi1-RlucII, GFP10-Gγ1, 
and GFP10-Gγ2 [25] were kindly provided by Dr. Michel Bouvier. The cDNA encoding the 
human Gβ1 subunit was obtained from the Missouri S&T cDNA Resource Center (Rolla, MO, 
USA). All constructs were verified by DNA sequencing. 
2.3. Cell culture and transfections 
HEK293 QBI cells (CRL-1573, from ATCC) were cultured in DMEM containing 20 mM HEPES, 
10% FBS, penicillin (100 U/mL), streptomycin (100 µg/mL), and glutamine (2 mM) under 5% 
CO2 at 37°C in a humidified atmosphere. Cells were used between passage numbers 4 to 25. For 
the transient expression of recombinant proteins, T75 flasks were seeded with 3 × 106 cells, and 
24 h later, the cells were transfected using PEI as previously described [26]. 
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2.4. BRET assays 
To monitor direct G protein activation, we used the following biosensor couples: GαoA-RlucII, 
GFP10-Gγ1, and Gβ1 [24] or Gαi1-RlucII, GFP10-Gγ2, and Gβ1 [25]. G protein biosensors and the 
hAPJ receptor were transfected into HEK293 QBI cells. At 24 h post-transfection, the cells were 
detached with trypsin-EDTA and plated (50,000 cells/well) in white opaque 96-well plates (BD 
Falcon, Corning, NY, USA). At 48 h post-transfection, the cells were washed once with PBS, and 
90 µL of HBSS containing 20 mM HEPES was then added. Ligands were added at increasing 
concentrations for 10 min followed by coelenterazine 400A (5 µM). BRET2 measurements were 
collected in the 400 to 450 nm window (Rluc) and in the 500 to 550 nm window (GFP10) using 
the BRET2 filter set on a GENios Pro plate reader (Tecan, Durham, NC, USA). The BRET2 ratio 
was determined as the light emitted by the acceptor GFP10 over the light emitted by the donor 
Rluc. The monitoring of βarr recruitment was done by the transient transfection of HEK293 QBI 
cells with plasmids containing cDNAs encoding hAPJ-GFP10 and Rluc-β-arrestin 1 or 2. The 
same protocol as the one used for G protein activation was then used. 
2.5. Lance Ultra cAMP assay 
The Lance Ultra cAMP assay was performed according to the manufacturer’s recommendations 
as previously described [19]. Briefly, 1,000 cells per well (384-well shallow well plate) were 
treated with increasing concentrations of compounds for 30 min in the presence of 1 µM forskolin. 
cAMP-tracer and anti-cAMP-Cryptate were added for at least 1 h. The plates were read on a 
GENios Pro plate reader with HTRF filters (excitation at 320 nm and emission at 620 and 665 
nm). The TR-FRET ratio was determined as the fluorescence of the acceptor (665 nm) over the 
fluorescence of the donor (620 nm). 
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2.6. Animal procedures 
All animal procedures were approved by the Ethical and Animal Care Committee of the Université 
de Sherbrooke and were in accordance with policies and directives of the Canadian Council on 
Animal Care. Furthermore, all animal studies comply with both the ARRIVE Guidelines 
(http://www.nc3rs.org.uk/page.asp?id=1357) and the National Institutes of Health guide for the 
care and use of laboratory animals. Adult male (250-300g) Sprague-Dawley rats (Charles River 
Laboratories, St-Constant, Québec, Canada) were maintained on a 12 h light/dark cycle with 
access to food and water ad libitum. Rats were acclimatized for 4 days to the animal facility prior 
to studies. 
2.6.1. Blood pressure measurement 
Male Sprague-Dawley rats were anesthetized with a mixture of ketamine/xylazine (87:13 mg/kg 
i.m.) and placed on a heating pad. Then, systolic, diastolic, and mean arterial pressure were 
measured every 30 seconds by the tail-cuff method, using the CODA Blood Pressure System (Kent 
Scientific Co., Connecticut, USA). When the blood pressure was stabilized (five consecutive 
measure with less than 5% variability), saline, apelin-13, or analogs was injected via the tail vein. 
Blood pressure measurements were acquired for seven minutes following compound delivery. 
Data used for Fig.3A were published, in part, in reference [19]. For the present study, the number 
of rats per dose of apelin-13 was increased and the dose of 10 mg/kg was added in order to fit a 
dose response curve. 
2.7. Data analysis for receptor activation parameters: EC50 and log(τ/KA) 
Each data set was normalized to the maximal response triggered by apelin-13, all values are 
expressed as the mean ± S.E.M. of at least three different experiments, which were each performed 
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in triplicate. EC50 values were obtained from normalized data and determined as the concentration 
of ligand showing 50% of activation. The data were calculated using concentration-response three 
parameters non-linear regression of GraphPad Prism 6 (La Jolla, CA, USA). 
The Black and Leff operational model describing receptor activation [27] was used to determine 
the transduction coefficient ! "#$% for each agonist using eq. (3), which is derived from the standard 
operational model equation, given by eq. (1): 
 & = ()×[,].×".[,].×"./([,]/#$). (1) 
Dividing above and below by 2, gave the ! "#$% ratio, as depicted in eq. (2): 
 & = ()×[,].×3 45$6.[,].×3 45$6./3[$]5$/76. (2) 
Dividing the member of eq. (2) by [A]9 × ! :;<%9simplified the equation and gave eq. (3): 
 E = >?7/@ [<]A<BC[<]×3 DA<6EF (3) 
In eq. (3), E is the effect triggered by the ligand, [A] is the concentration of ligand, Em represents 
the maximum response of the system (this is not the same as the Emax, which represents the 
maximal response of the ligand), n is the transducer slope that links occupancy to response (this is 
not the same as the Hill slope derived from logistic curve fitting, but these two parameters are 
closely related [28]), KA depicts the functional equilibrium dissociation constant, and τ denotes the 
operational agonist’s efficacy. Em and n are specific of the cell, they are thus shared by all agonists; 
whereas, τ and KA are specific of the ligand. 
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Fitting experimental data to eq. (3) could result in multiple combinations of τ and KA, therefore, 
the transduction coefficient, defined by eq. (4), was used as a parameter to define the agonism for 
a given pathway at a given receptor:  
 GHIJKLMNOPQJ	NQSTTPNPSJO = UQV ! "#$% (4) 
To eliminate the observational and system bias, ligand activity at a given pathway was divided by 
the activity of the reference compound, apelin-13 (APE), for the same pathway using eq. (5): 
 ∆	UQV ! "#$% = 	 UQV ! "#$%XYZ − UQV ! "#$%,\( (5) 
The relative efficacy of an agonist toward a given pathway, relative to the reference compound 
APE, was calculated as the anti-logarithm of the ∆	UQV ! "#$% by eq. (6): 
 ]SUIOP^S	STTPNIN_	(]&) = 10∆	Xbc3 45$6 (6) 
The standard error of the mean (S.E.M.) of the transduction coefficient UQV ! "#$% was calculated 
by using eq. (7): 
 d. &.f.gbc3 45$6 	= 	 h√j (7) 
In eq. (7), σ represents the standard deviation calculated from each separate experiment and n is 
the number of separate experiment performed. 
Eq. (8) was used to calculate S.E.M. for the ΔUQV ! "#$% to avoid the propagation of the error during 
the subtraction step used to calculate the normalized transduction coefficient: 
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 d. &.f.∆gbc3 45$6 	= 	lmd. &.f.gbc3 45$6XYZ no − md. &.f.gbc3 45$6,\( no (8) 
Standard parameters describing ligand-induced receptor activation (namely EC50 and Emax) are 
closely related with the Black and Leff operational model of receptor activation. EC50 is linked to 
it by eq. (9): 
 ECqr = #$(o/".)C.s7 (9) 
and Emax by eq. (10): 
 &tuv = ()".7/". (10) 
2.8. Data and statistical analyses for the in vivo procedures 
The ED50 value of the hypotensive effect of apelin-13 was determined as the concentration of 
apelin-13 showing 50% of the maximal hypotensive response. Each data point on the dose-
response curve represents the maximal hypotensive response of each dose of apelin-13. The data 
were calculated using dose-response three parameters non-linear regression of GraphPad Prism 6.  
Statistical analyses were performed using GraphPad Prism 6 and are described in the figure legend 
when applicable. A value was considered statistically significant when p < 0.05. 
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3. Results and discussion 
3.1. Chemical modification of the Phe13 residue results in significant changes in APJ 
receptor binding and signaling  
Before assessing the signaling pathways activated by apelin-13 and its C-terminal modified 
analogs (structures of the analogs are presented in Scheme 1), we first characterized their binding 
affinities on the human APJ receptor expressed in HEK293 cells. IC50 values for each apelin-13 
analog are summarized in Table 1. The IC50 of the endogenous reference compound apelin-13 was 
1.2 nM while some tested analogs carrying unnatural amino acids (compounds 3, 5, 6, and 8) 
exhibited higher affinities ranging from 0.02 to 0.48 nM. Other C-terminally modified analogs 
were found to have lower affinities when compared to apelin-13 (compounds 2, 4, 7, 9, and 10; 
with IC50 ranging from 6.1 to 68.2 nM). These results are in accordance with previous alanine and 
D-amino acid scanning data, suggesting that modification of the N-terminal region (i.e. Arg2-Pro3-
Arg4-Leu5) as well as C-terminal residue substitutions significantly affect apelin-13 binding to APJ 
[5,18,19]. 
To dissect the signaling pathways engaged by this series of apelin-13 analogs, we first assessed 
the ability of these compounds to activate Gαi/o in HEK293 cells transiently overexpressing the 
APJ receptor. To this end, we used inhibition of the forskolin-induced cAMP production as an 
endpoint (Table 1 and Fig. 1A). We then monitored the activation of both the Gαi1 and the GαoA 
pathways at the direct G protein level. Activation of Gαi1 by APJ was determined using a BRET-
based assay by measuring the dissociation between Gαi1-RlucII and Gγ2-GFP10 (Table 1 and Fig. 
1B). The same BRET-based cellular approach was used to monitor the activation of GαoA by using 
the GαoA-RlucII and Gγ1-GFP10 constructs (Table 1 and Fig. 1C) or to measure the ability of 
This is the accepted (postprint) version of the following article: Besserer-Offroy É, et al. (2018), 
Pharmacol Res. doi: 10.1016/j.phrs.2018.02.032, which has been accepted and published in its 
final form at https://www.sciencedirect.com/science/article/pii/S1043661817313804 
 
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 
license http://creativecommons.org/licenses/by-nc-nd/4.0/  
 15 
these apelin-13 analogs to recruit β-arrestins 1 and 2 (βarrs) to activated APJ-GFP10 receptor 
(Table 1 and Fig. 1D, E). The use of cells endogenously expressing APJ would have been more 
relevant, however this was not technically feasible since we need to use the APJ-GFP10 
recombinant construct to monitor the recruitment of the Rluc-βarrs at APJ by BRET.  
In the cellular functional assays, all compounds acted as full agonists in both the inhibition of 
cAMP production and Gαi/o assays, as they triggered a maximal response (Emax) comparable to 
apelin-13 (Supplementary Table S1). The potency (EC50) of these analogs to inhibit the 
forskolin-induced cAMP production closely paralleled their binding affinities. Indeed, compounds 
6 and 8 were extremely effective at inhibiting cAMP production, with a 20- to 30-fold gain 
compared to apelin-13. In contrast, compound 7 was found to be more than 100-fold less potent at 
inhibiting cAMP formation, when compared to apelin-13 (Table 1). BRET-based assays 
monitoring the engagement of Gαi1 and GαoA revealed potencies in the same order of magnitude 
as for the reference ligand apelin-13 (Table 1). Consequently, we did not observe a direct 
correlation between cAMP inhibition and Gαi/o activation. Compounds 6 and 8 displayed an 
increase in cAMP inhibition accompanied with no or very small changes in Gαi1 and GαoA 
activation. Likewise, compound 7 showed a 5-fold decrease in Gαi1 activation, no change in GαoA 
activation while inhibiting cAMP production with 100-fold less potency. In explanation of these 
discrepancies between cAMP inhibition and G protein activation, it may be argued that C-terminal 
modified analogs recruit distinct Gαi/o isoforms than Gαi1 and GαoA, such as Gαi2,3 or GαoB to 
inhibit cAMP production [29]. This hypothesis is supported by the fact that the apelin fragments 
promote the coupling of APJ to either Gαi1 or Gαi2 but not to Gαi3 [30]. Differences between cAMP 
inhibition and Gαi/o activation may also arise from activation specificities among the nine cloned 
This is the accepted (postprint) version of the following article: Besserer-Offroy É, et al. (2018), 
Pharmacol Res. doi: 10.1016/j.phrs.2018.02.032, which has been accepted and published in its 
final form at https://www.sciencedirect.com/science/article/pii/S1043661817313804 
 
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 
license http://creativecommons.org/licenses/by-nc-nd/4.0/  
 16 
isoforms of adenylyl cyclase (AC) [31]. Indeed, AC must be pre-stimulated, generally using 
forskolin to induce cAMP production in order to measure inhibition of the enzyme in a second 
step. Despite wide use in cell-based high-throughput screening assay, this approach is at risk of 
biased interpretations since forskolin preferentially activates ACI, ACV or ACVI and may also bind 
different adenylyl cyclase regions than G-proteins thus inducing different conformations of the 
enzyme catalytic core [32-34].  
To further investigate the signaling signature of these apelin-13 analogs, we studied βarr 
recruitment to APJ by measuring BRET signals of Rluc-βarr 1 or 2 association to activated APJ-
GFP10 receptor in living cells (Table 1 and Fig. 1D, E). Interestingly, the substitution of the C-
terminal Phe13 residue of apelin-13 led to different classes of compounds displaying distinct βarr 
recruitment profiles. Indeed, replacement of Phe13 by a lipophilic amino acid such as Val or Ala 
(compounds 2 and 10, respectively) decreased the recruitment of both βarrs whereby compound 
10 appeared to act as a partial agonist in this paradigm (Table 1 and Supplementary Table S1). 
Substitution of Phe13 with a residue having a shortened side chain residue (PheGly, compound 9) 
was also deleterious for recruiting βarrs with a near 5-fold loss compared to the endogenous ligand, 
apelin-13. On the other hand, replacing Phe13 with Phe(4Me), an electron donating residue 
(compound 3), or with amino acids having increased electron density and steric hindrance (such 
as Tyr(OBn) or Bpa, compounds 5 and 6, respectively), led to an improvement in βarr 1 and βarr 
2 recruitment. These results indicate that two physical properties, length and steric hindrance of 
residue 13’s side chain, play a critical role in recruiting βarrs by APJ. We postulate that APJ’s 
orthosteric sub-binding pocket accommodating apelin-13’s C-terminal residue needs to be entirely 
filled to induce βarr recruitment. It has been previously shown that this sub-pocket can 
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accommodate residues with large aromatic side chains but there is a limit of steric hindrance the 
pocket can tolerate [18]. Indeed, the substitution of Phe13 with dihydroanthranylAla residue 
(compound 7) had a deleterious effect on βarr recruitment. In fact, this compound elicited a 5- and 
12-fold loss of βarr 1 and βarr 2 recruitment when compared to apelin-13, respectively (Table 1). 
This negative effect of large side chain residues has been previously observed with a 
diphenylalanine substitution which led to a 7-fold decrease in βarr 2 recruitment [18]. Furthermore, 
these findings are supported by the recent published X-ray crystallographic structure of APJ in 
complex with an apelin-17 derivative showing the shape of the C-terminal cavity delineated by 
side chains of Y35, W85, Y88, Y93 and Y299 [35]. Finally, the (L-α-Me)Phe substitution 
(compound 8) was found to improve βarr recruitment compared to apelin-13 (7- and 4-fold 
increase, respectively) which led to one of the most potent apelin-13 analog reported to date [19]. 
Altogether, these results revealed that modifications of the C-terminal Phe13 residue exert only 
small effects on the activation of Gαi/o. This is in accordance with previous findings demonstrating 
that the C-terminal end of apelin-13 and apelin-17 (Lys-Phe-Arg-Arg-apelin-13) does not play a 
major role in the inhibition of cAMP production [5,12,21]. In sharp contrast, the substitution of 
the C-terminal Phe13 residue significantly affects the ability of these modified analogs to recruit β-
arrestins. Accordingly, deletion or replacement of the C-terminal residue in apelin-13 or apelin-17 
by Ala also influences APJ receptor internalization [12,21,22]. In addition to these in vitro 
observations, the single C-terminal amino acid modification further abolishes the ability of these 
analogs to modulate blood pressure in vivo, thus demonstrating the importance of the role played 
by this residue in the APJ-triggered MABP lowering [12,36]. 
3.2. Determination of the “within-pathway” relative efficacy of the analogs 
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Characterization and quantification of the agonist’s activity should be evaluated in a manner that 
allows the use of statistical methods to compare the differences in agonist activity of the tested 
analogs. Traditional methods, such as comparison of pEC50 or Emax values, are inadequate due to 
system bias [37]. To properly quantify the agonistic properties of our analogs, we thus applied the 
Black and Leff operational model to assess the relative efficacy of our compounds compared to 
apelin-13 [28]. Considering affinity as well as agonist’s efficacy, the Black and Leff [27] 
operational model specifically quantifies the transduction coefficient defined by Log(τ/KA) which 
fully characterizes the selective activation of cellular signaling pathways by a given agonist. A 
comprehensive procedure of transduction coefficient quantification is detailed in the methods 
section and in the supporting information (Supplementary Note S1). 
Using eq. (3), each concentration-response curve was fitted with the Black and Leff operational 
model describing receptor activation to derive the transduction coefficient, log(τ/KA), as a 
representation of the analog effect on receptor ability to trigger different signaling pathways 
(Supplementary Table S2). Since apelin-13 is the endogenous ligand of APJ, it was used as the 
reference ligand to which all other ligands were referred to in a “within-pathway” comparison 
using eq. (5), resulting in the Δlog(τ/KA), the normalized transduction coefficient. The relative 
efficacy (RE) of the analogs for each pathway, relative to apelin-13, was determined by eq. (6). 
The normalized transduction coefficient (Δlog(τ/KA)) and RE are reported in Table 2. A graphical 
representation of the agonist activity of each analog for all the studied pathways is represented in 
Fig. 2. Compounds 2, 4, 7, 9, and 10 exhibited similar profiles and were generally less potent than 
the reference apelin-13 to trigger a cellular response. However, compounds 3, 5, 6, and 8 either 
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showed similar or slightly improved profiles in terms of efficacy when compared to apelin-13. We 
then quantified the action of our compounds on the APJ-mediated hypotensive action. 
3.3. Hypotensive effect of apelin-13 and analogs 
We first determined the hypotensive action of different doses of the reference ligand apelin-13 by 
measuring the MABP, in response to a bolus injection, using a non-invasive tail-cuff system in 
anesthetized male rats. Apelin-13 triggered a rapid and transient MABP drop that returned to basal 
levels within 6 minutes following intravenous injection (Fig 3A). This hypotensive action of 
apelin-13 was found to be dose-dependent with a determined ED50 of 0.12 ± 0.04 mg/kg (Fig. 3B). 
We further demonstrated that the hypotensive action of apelin-13 is dependent on the activation of 
the NO-dependent signaling pathway since L-NAME, a nitric oxide synthase inhibitor, totally 
abolished apelin-13-triggered MABP drop (Supplementary Fig. S1). The acute activation of the 
apelinergic system observed here is in accordance with previous findings showing that single 
intravenous injection of apelin-13 in Inactin-anesthetized male Wistar rats led to a rapid blood 
pressure lowering that last no more than 3-4 min [2,38-40]. Based on these results, it was argued 
in the literature that the APJ receptor might be a promising therapeutic target in the context of 
hypertension and pulmonary arterial hypertension [41,42]. Accordingly, the group of Davenport 
recently demonstrated that daily intraperitoneal injection of ELABELA, a second short-lived 
endogenous agonist peptide that binds APJ, significantly reduces the pathology of monocrotaline-
induced rat model of pulmonary arterial hypertension [43]. Furthermore, acute apelin injection 
was previously reported to transiently reduce the MABP of spontaneously hypertensive rats almost 
as efficient as seen in Wistar-Kyoto control rats [44]. Altogether, these results suggest that 
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targeting the apelinergic system might indeed be therapeutically relevant in the context of 
hypertension.  
In order to use a dose that would allow us to detect whether our analogs were more or less potent 
than apelin-13 to lower the MABP, we then monitored the hypotensive response induced by our 
compounds at a dose of 0.1 mg/kg, which corresponded to the determined ED50 of apelin-13. The 
maximum drop of MABP measured after iv injection of our analogs is shown in Fig. 3C. 
Compounds 2, 3, 5 and 8 were found to reduce MABP, similarly to apelin-13. Compounds 4, 6, 
and 9 triggered an intermediate MABP drop between apelin-13 and saline injections. Furthermore, 
the ΔMABP of those compounds were not significantly different from apelin-13 or saline 
injections. Finally, compounds 7 and 10 did not elicit reductions in blood pressure having similar 
profiles to saline (complete time courses of the blood pressure response for all the analogs are 
presented in Supplementary Fig. S2). These results allowed us to differentiate three classes of 
compounds: compounds that had similar properties to apelin-13, compounds exhibiting an 
intermediate profile and compounds that did not induce MABP lowering. We then attempted to 
see whether a comparable clustering of compounds existed within a particular APJ receptor 
signaling pathway, thereby correlating physiological effects and cell signaling. Previous results 
suggested that the MABP drop induced by apelin peptides is mediated by a Gαi/o-independent 
signaling pathway but potentially triggered by an internalization-related pathway [12,19,22]. We 
found that compounds with a MABP reducing behavior similar to apelin-13 usually had a βarr 
recruitment RE equivalent to that of apelin-13, whereas the intermediate compounds possessed a 
βarr recruitment RE between 1- and 5-fold less than apelin-13. Finally, compounds 7 and 10 were 
found to have a βarr recruitment RE of 5- to 15-fold less than the reference. These results prompted 
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us to link βarr recruitment to the hypotensive effect of the compounds. We first assessed whether 
the normalized transduction coefficients found for all analogs were significantly different from the 
one of apelin-13 for each of the studied signaling pathways in a Kruskal-Wallis followed by a 
Dunn’s post hoc test (Supplementary Table S3). To confirm our hypothesis and since at least one 
analog possessed a normalized transduction coefficient significantly different from apelin-13 in 
each signaling assay, we performed different correlations between the ΔMABP and the 
Δlog(τ/KA) for each studied pathway (Fig. 4 and Supplementary Fig. S3). Only the two 
correlations with the Δlog(τ/KA) for βarr recruitment were found to be statistically significant, 
whereas no correlations were found between ΔMABP and the Δlog(τ/KA) for the Gαi/o-related 
pathways (i.e. cAMP inhibition, Gαi1, and GαoA). Spearman correlation of ΔMABP and 
Δlog(τ/KA)β-arrestin 1 was found to be statistically significant with a p value of 0.0022 and a r of 
0.867 (Fig. 4A). The same correlation with Δlog(τ/KA)β-arrestin 2 was also found significant with a 
p value of 0.0016 and a r of 0.879 (Fig. 4B). 
In the present study, we thus demonstrate the key role played by the C-terminal residue of apelin-
13 for the modulation of βarr recruitment to APJ and the involvement of this signaling pathway in 
the hypotensive response mediated through APJ. We also found that modulation of the βarr 
recruitment by substituting Phe13 with natural and unnatural amino acids led to the modulation of 
the blood pressure lowering effect. This is also confirmed by a recent study aimed at developing 
apelin-13 macrocyclic analogs where three compounds (compounds 7, 15 and 20; structures of 
these compounds can be found in Supplementary Scheme S1, upper panel) were shown to induce 
a hypotensive effect significantly different from the one mediated by apelin-13 at an equimolar 
dose [45]. When looking at the activation profile of those analogs, we further observed that those 
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three compounds had a decreased ability to induce βarr recruitment compared to apelin-13 while 
they conserved their capacity to bind to APJ and to activate Gαi1 and GαoA pathways. Likewise, 
the cyclic apelin peptide MM07, which preferentially activates G-protein coupling over βarr 
signaling was reported to be not effective in lowering MABP [46].  
Furthermore, this structure-activity relationship (SAR) was also true when assessing the second 
endogenous ligand of APJ, ELABELA/Toddler. Indeed, the discovery and SAR of the minimally 
bioactive fragment of ELABELA/Toddler revealed two compounds (compounds 3 and 4; see 
compound’s structures in Supplementary Scheme S1, lower panel) that displayed biased profiling 
comparable to the one observed for the macrocyclic compounds [47]. Those two compounds 
exhibited lower efficacies at recruiting βarr 2 and lower reduction of MABP. Altogether, our 
results, as well as previously published findings indicate that βarr recruitment at the APJ receptor 
represents the initiating signaling step that regulates the hypotensive action mediated by apelin 
peptides. Interestingly, ELA(19-32), compound 3, still triggers an increased left ventricular 
developed pressure (LVDP) in the same range of apelin-13 while its potency to mediate a 
hypotensive response is decreased. This suggests that the inotropic effect of APJ is mediated 
through a signaling pathway distinct from βarr recruitment [8]. 
It has already been proposed that βarr recruitment plays an important role in blood vessel 
relaxation. Indeed, apelin-17 was shown to counteract angiotensin II mediated glomerular arteriole 
constriction while apelin-17 lacking the C-terminus amino acid (K16P) had no effect on arteriole 
diameter [22]. The authors thus concluded that apelin-17 caused a decrease in MABP through a 
βarr-dependent ERK1/2 activation process. Following binding to APJ, apelin-13 has, however, 
been shown to provoke PTX-sensitive ERK1/2 phosphorylation via a PKC-dependent mechanism 
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in a Ras-independent manner [17]. It is therefore unlikely here that the hypotensive action of 
apelin-13, mediated via the βarr-dependent pathway, relies on the activation of the ERK1/2 
signaling cascade. This is not the first time that the binding of different apelin fragments (i.e. 
apelin-13, -17 or -36) to the APJ receptor behaves differently. Lee et al., have previously reported 
that apelin-13 induces a rapid recycling of the receptor to the cell surface after internalization via 
a Rab4-dependent process, whereas apelin-36 internalized receptors remain associated with 
βarrestins and are targeted to the lysosomal compartment by Rab7 [20]. Likewise, it was also 
demonstrated that short and long forms of apelin exhibit distinct desensitization profiles. Indeed, 
the deletion of the C-terminal tail of APJ decreases the desensitization pattern induced by apelin-
36 without altering the desensitization profile related to APJ activation by apelin-13 [30]. 
The hypotensive action of apelin has been shown to be mediated through a NO-dependent 
mechanism since L-NAME blocked the apelin-mediated MABP lowering. [12,48]. Therefore, the 
link between βarr recruitment and NO production needs to be addressed. The serine/threonine 
kinase, Akt, has been shown to be activated by several proteins such as PI3K and βarrs [49-51] 
and has also been linked to the activation of the endothelial isoform of NO-synthase [52]. We can 
therefore hypothesize that activation of Akt could stimulate NO production in endothelial cells by 
a βarr-dependent mechanism. This is of particular interest since apelin, following binding on APJ, 
was shown to induce the phosphorylation of Akt in endothelial cells [53,54]. Furthermore, 
mechanical stretch has been recently reported to activate APJ in a biased manner by favoring βarr 
over Gαi/o signaling [55,10]. Thus, this mechanism could play a protective role by inducing a 
hypotensive response, hence decreasing mechanical stretch. 
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4. Conclusion 
We have demonstrated that the hypotensive effect mediated by APJ is significantly correlated with 
the recruitment of βarrs. Furthermore, we identified that the recruitment of βarr can be modulated 
by modifying the C-terminal residue of apelin-13 and that potent agonists at stimulating βarr 
translocation were effective in lowering MABP. We bring new insight into APJ-mediated 
signaling and the relationship that exists between the physiological action of a hormone and its 
downstream signaling pathways. Further studies are, however, required to discriminate which 
signaling pathway, acting downstream of βarr activation, is involved in the hypotensive action 
mediated by apelin binding to APJ. Finally, the development of biased apelin receptor agonists 
will be of great interest to decipher the physiopathological roles played by the apelinergic axis and 
to potentially offer new and effective treatment options for cardiovascular disease. 
 
5. Supplementary material 
Fitting parameters and equations to retrieve ligand-specific parameters of receptor activation using 
GraphPad Prism, structure of cited macrocyclic analogs of apelin-13 and ELABELA analogs, 
effect of L-NAME on apelin-13-mediated hypotensive response, time-course of the hypotensive 
response triggered by the apelin analogs, correlations between ΔMABP and the Δlog(τ/KA) for 
the Gαi/o-related pathways, Emax table, log(τ/KA) table, and statistical analysis of Δlog(τ/KA) 
table are available as supplementary information PDF file. 
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Schemes, Figures, and Tables  
 
 
 
 
Scheme 1. Developed structures of apelin-13 and analogs used in this study.  
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Fig. 1. Activation of signaling pathways triggered by apelin-13 and four representative C-
terminally modified analogs. (A) Ligand-mediated inhibition of the forskolin-stimulated 
accumulation of cAMP measured using PerkinElmer’s Lance Ultra cAMP assay. (B-C) Ligand-
triggered engagement of the G protein pathways Gαi1 (B) and GαoA (C) monitored using the 
BRET-based G protein dissociation assay. (D-E) Ligand-induced recruitment of βarr 1 (D) and 
βarr 2 (E) using the BRET-based βarr recruitment assay. Each data set represents the mean of three 
independent experiments, each performed in triplicate, and expressed as the mean ± S.E.M.  
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Fig. 2. Relative efficacy plots for each analog. The normalized transduction coefficient 
(Δlog(τ/KA)), as calculated using the Black and Leff operational model, was graphed for each 
studied signaling pathway. Values for each analog are represented by the solid colored line and 
apelin-13’s values are represented on each graph by the gray dashed line. Each point on graphs 
represents the mean Δlog(τ/KA) of the analog for the specified signaling pathway and was 
calculated using concentration-response curves, which were the result of three independent 
experiments. 
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Fig. 3. Effects of apelin-13 and C-terminally modified analogs on blood pressure. (A) Effect 
of increasing doses of apelin-13 (i.v. injection) on the mean arterial blood pressure (MABP) of 
anesthetized rats, measured using non-invasive blood pressure recording. (B) Dose-response curve 
of apelin-13’s hypotensive effects. Each point represents the maximum blood pressure drop as 
recorded on panel A. (C) Effect of the i.v. injection of saline (SAL, 0.1 mL/kg), apelin-13 (APE) 
or the analogs (0.1 mg/kg) on the MABP of anesthetized rats. Each value represents the mean ± 
S.E.M. obtained with 6-8 rats. Statistical analysis was performed on the ΔMABP values using the 
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Kruskal-Wallis multiple comparisons followed by a Dunn’s post-hoc test. * p < 0.05, ** p < 0.01 
compared to saline; $$ p < 0.01 compared to apelin-13.  
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Fig. 4. Correlations between the hypotensive effect and the relative efficacy of βarr 
recruitment. (A) Correlation between the ΔMABP and the normalized transduction coefficient 
for βarr 1 recruitment, denoted by the Δlog(τ/KA)β-arrestin 1. (B) Correlation between the ΔMABP 
and the normalized transduction coefficient for βarr 2 recruitment, denoted by the Δlog(τ/KA)β-
arrestin 2. Each point represents the mean ± S.E.M. of the ΔMABP in the y-axis and the S.E.M. of 
the Δlog(τ/KA) in the x-axis. Colors denote the ability to induce a hypotensive response, red dots 
represent analogs statistically different from apelin-13, light green dots represent analogs not 
statistically different from saline or apelin-13, and dark green dots represent analogs statistically 
different from saline. The gray dot represents the reference compound apelin-13 as represented in 
Fig. 3C. Statistical analysis was performed using the Spearman correlation; r coefficient and p 
values are reported on each graph, a p < 0.05 was considered significant. 
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Analog sequence 
binding 
IC50 (nM)a 
functional assaysb 
cAMPi 
EC50 (nM) c 
Gαi1 
EC50 (nM) 
GαoA 
EC50 (nM) 
βarr 1 
EC50 (nM) 
βarr 2 
EC50 (nM) 
1 apelin-13 1.2 ± 0.1 1.8 ± 0.4 0.39 ± 0.07 6.2 ± 1.4 24 ± 1.4 52 ± 13 
2 [Nle11, Val13]apelin-13 18.2 ± 3.2 6.9 ± 3.4 0.52 ± 0.03 3.4 ± 1.1 81 ± 3 232 ± 99 
3 [Nle11, Phe(4-Me)13]apelin-13 0.25 ± 0.02 0.13 ± 0.01 0.56 ± 0.02 3.0 ± 1.5 3.4 ± 1.5 33 ± 26 
4 [Nle11, (2-pyridyl)Ala13]apelin-13 6.1 ± 1.0 4.8 ± 2.5 0.32 ± 0.05 2.2 ± 0.6 18 ± 5.9 35 ± 6.8 
5 [Nle11, Tyr(OBn)13]apelin-13 0.02 ± 0.003 0.31 ± 0.16 0.49 ± 0.21 1.5 ± 0.5 7.2 ± 2.6 14 ± 5.5 
6 [Nle11, Bpa13]apelin-13 0.48 ± 0.05 0.06 ± 0.01 0.64 ± 0.30 4.0 ± 2.0 13 ± 3.4 38 ± 10 
7 [Nle11, AnthranylAla13]apelin-13 13.7 ± 1.6 217 ± 51 2.14 ± 0.18 5.1 ± 1.3 133 ± 10 628 ± 223 
8 [Nle11, (L-α-Me)Phe13]apelin-13 0.43 ± 0.03 0.09 ± 0.03 2.32 ± 0.85 3.6 ± 1.5 3.2 ± 1.8 15 ± 7.0 
9 [Nle11, PheGly13]apelin-13 14.3 ± 1.4 2.4 ± 0.4 1.62 ± 0.20 10.3 ± 3.9 102 ± 24 247 ± 160 
10 [Ala13]apelin-13 68.2 ± 15 8.84 ± 1.3 2.41 ± 0.97 1.9 ± 0.6 425 ± 303 154 ± 98 
aValues of binding are from [19]. IC50 values represent the concentration of ligand inhibiting 50% of the radioligand binding. bEC50 values 
represent the concentration of ligand showing 50% of pathway’s activation. ccAMPi refers to the inhibition of the forskolin-induced cAMP 
production. 
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Table 1. Binding affinity and Gαi/o, cAMP inhibition, and βarr recruitment potencies of C-terminally modified apelin-13 analogs. 
Each value represents the mean of three independent experiments, which were each done in triplicate, and is expressed as the mean ± 
S.E.M. 
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Analog 
cAMPia Gαi1 GαoA βarr 1 βarr 2 
Δlog(τ/KA) RE Δlog(τ/KA) RE Δlog(τ/KA) RE Δlog(τ/KA) RE Δlog(τ/KA) RE 
1 0.00 ± 0.07 1.00 0.00 ± 0.22 1.00 0.00 ± 0.26 1.00 0.00 ± 0.07 1.00 0.00 ± 0.14 1.00 
2 -0.61 ± 0.11 0.25 -0.60 ± 0.25 0.25 1.01 ± 0.26 10.26 -0.60 ± 0.08 0.25 -0.74 ± 0.16 0.18 
3 0.68 ± 0.11 4.81 -0.16 ± 0.24 0.70 1.09 ± 0.26 12.39 0.95 ± 0.07 8.95 0.51 ± 0.13 3.22 
4 0.05 ± 0.14 1.12 -0.45 ± 0.23 0.36 0.32 ± 0.25 2.09 -0.57 ± 0.07 0.27 -0.61 ± 0.18 0.24 
5 0.45 ± 0.11 2.85 -0.14 ± 0.22 0.72 0.91 ± 0.26 8.09 0.57 ± 0.06 3.74 0.38 ± 0.14 2.38 
6 1.71 ± 0.09 51.40 -0.09 ± 0.22 0.81 0.62 ± 0.27 4.14 0.30 ± 0.06 1.97 -0.09 ± 0.15 0.81 
7 -2.09 ± 0.14 0.01 -0.86 ± 0.24 0.14 0.38 ± 0.26 2.40 -0.64 ± 0.07 0.23 -1.08 ± 0.17 0.08 
8 1.37 ± 0.12 23.5 -0.62 ± 0.25 0.24 0.46 ± 0.26 2.88 0.91 ± 0.07 8.17 0.57 ± 0.14 3.75 
9 -0.32 ± 0.11 0.47 -0.87 ± 0.23 0.13 0.04 ± 0.25 1.10 -0.58 ± 0.07 0.26 -0.62 ± 0.15 0.24 
10 -0.86 ± 0.10 0.14 -0.54 ± 0.29 0.29 1.64 ± 0.26 43.75 -1.23 ± 0.17 0.06 -1.03 ± 0.27 0.09 
acAMPi refers to the inhibition of the forskolin-induced cAMP production. 
Table 2. Normalized transduction coefficient (Δlog(τ/KA)) and relative efficacy (RE) of C-terminally modified apelin-13 analogs. 
Each value represents the mean of three independent experiments, done in triplicate, and expressed as the mean ± S.E.M. 
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The hypotensive effect of activated apelin receptor is correlated with 
β-arrestin recruitment  
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Supplementary Note S1. Fittings parameters and equations to retrieve ligand-specific 
parameters of receptor activation using GraphPad Prism. 
 
Selection of the reference agonist: Any ligand could be defined as the reference agonist providing 
it is a full agonist on each of the assessed pathways. 
 
The following code is used to program a non-linear curve fit to retrieve ligand-specific parameters 
of receptor activation with GraphPad Prism v6 and higher: 
1. Open GraphPad Prism and create a new user-define equation: 
Go to Analyse  > Create new equation  
2. In the equation tab, select “Explicit Equation: Y = a function of X and parameters” 
3. Name your new equation: “Black and Leff operational model” 
4. In the definition panel enter the following: 
A_T=10^(X*n)*10^(LogT*n) 
Y=Emax*A_T/[A_T+(10^X+10^LogKA)^n] 
5. Go to the “Rules for Initial Values” tab and enter the following: 
Parameter Value Rule 
n 2 Initial value, to be fit 
LogT 0.1 Initial value, to be fit 
Emax 100 Initial value, to be fit 
LogKA -8 Initial value, to be fit 
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Select: Start graphing the curve at the smallest X value 
6. Go to the “Default Constraints” tab and enter the following: 
Parameter Constraint Value 
n Shared value for all dataset - 
LogT No constraint - 
Emax Constant equal to 100 
LogKA No constraint - 
 
7. Go to the “Default Constraints” tab and enter the following: 
a. In “Report transforms of best-fit parameters (with 95% CI)”: 
KA = 10^LogKA  CI method: Asymetrical 
T = 10^LogT   CI method: Asymetrical 
b. In “Report these combinations of best-fit parameters (with 95% CI)”: 
Log(T/KA) = P1 - P2  P1 = LogT  P2 = LogKA 
 
8. Your new custom equation is now configured. You can retrieve it under: 
Analyse > Nonlinear regression > User-defined equation > Black and Leff operational model 
9. To analyze your data, create a new XY spreadsheet and enter the normalized values from 
your assay into column A and subsequent. Then, retrieve your custom equation and apply 
the analysis. 
10. If curve fit does not work (Ambigous), modify the Emax constraint and enter the Emax of 
the reference ligand. 
11. The Log(T/KA) is given directly in “results of nonlinear fit”.
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Supplementary Scheme S2. Developed formulae of compounds 7, 15, and 20 (from the reference 38) and developed formulae of 
compounds 3 and 4 (from the reference 40).  
  
HN
HN
N
H
N
O
O
O
O
O
H
N
O
N
H
O
H
N
O
N
H
O
N
O
H2N
NH2
HO
HN
HN
NH
H2N
H2N
NH
Arg
Pro
Arg
Ser
Lys
Gly
Pro
Leu
HN
O
OH
O
Tyr(OBn)
N
O
Pro
Compound 7
(from reference 38)
HN
HN
N
H
N
O
HN O
O
O
O
H
N
NH2
Lys
Gly
Pro
O
HO
O
Tyr(OBn)
H
N
H
O
NH2
N
O
Lys
N
H
O
NH2
H
N
O
Ser
N
H
O
OH
Lys
HN
HN
N
H
N
O
HN O
O
O
O
H
N
NH2
Lys
Gly
Pro
O
HO
O
Tyr(OBn)
N
H
O
HN
NHH2N
N
O
N
H
O
HN
NH
H2N
H
N
O
N
H
O
OH
O
Compound 15
(from reference 38)
Compound 20
(from reference 38)
HO
O
NH
O
NH
NH
H2N
HN
O
N
H
HN
NH2
NH
O
HS
NH
O
S
N
O
H
N
O
N
H
O
N
H
N
H
N
O
OH
N
H
O
NH
HN NH2
H
N
O
N
O
HN
O
N
O
HN
O
Pro
Leu
Arg
Pro
Leu
Arg
Ser
Arg
Pro
Arg
Cys
Met
Leu
Leu
Arg
Ser Val Pro
Pro
Phe
HO
H2N
O
HS
NH
O
S
N
O
H
N
O
N
H
O
N
H
N
H
N
O
OH
N
H
O
NH
HN NH2
H
N
O
N
O
HN
O
N
O
Pro
Cys
Met
Leu
Leu
Arg
Ser Val Pro
Pro
Phe
Compound 3
(from reference 40)
Compound 4
(from reference 40)
This is the accepted (postprint) version of the following article: Besserer-Offroy É, et al. (2018), 
Pharmacol Res. doi: 10.1016/j.phrs.2018.02.032, which has been accepted and published in final 
form at https://www.sciencedirect.com/science/article/pii/S1043661817313804 
 
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 
license http://creativecommons.org/licenses/by-nc-nd/4.0/  
 S6 
 
 
Supplementary Fig. S1. Time course of the blood pressure response triggered by the bolus 
injection of apelin-13 in L-NAME- or vehicle-treated rats. The grey solid line represents the 
effect of a 0.1 mg/kg dose of apelin-13 injected as a bolus in vehicle-treated animals. The black 
(filled squares) line represents the effect of a bolus injection of apelin-13 at a dose of 0.1 mg/kg 
in animals pre-treated with 5 mg/kg of the NO-synthase inhibitor L-NAME. Bolus injection of 
apelin-13 was done 15 minutes after vehicle or L-NAME treatment. Each point represents the 
mean ± S.E.M. obtained with 5-8 rats.  
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Supplementary Fig. S2. Time course of the blood pressure response triggered by the bolus 
injection of apelin-13 analogs. (A) Compound 2. (B) Compound 3. (C) Compound 4. (D) 
Compound 5. (E) Compound 6. (F) Compound 7. (G) Compound 8. (H) Compound 9. (I) 
Compound 10. The black solid line represents the effect of saline injection. (J) Area under the 
curve for saline injection (SAL), apelin-13 (APE-13), and each of the analogs (2-10). Each point 
represents the mean ± S.E.M. obtained with 6-8 rats. Statistical analysis was performed on the 
AUC values using the Kruskal-Wallis multiple comparisons followed by a Dunn’s post-hoc test. 
* p < 0.05, ** p < 0.01 compared to saline; $ p < 0.05 compared to apelin-13. 
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Supplementary Fig. S3. Correlations between the hypotensive effect and the efficacy to 
activate Gαi/o and cAMP signaling pathways. (A) Correlation between the ΔMABP and the 
normalized transduction coefficient for the inhibition of cAMP production, denoted by the 
Δlog(τ/KA)cAMPi. (B) Correlation between the ΔMABP and the normalized transduction 
coefficient for the activation of the Gαi1 pathway, denoted by the Δlog(τ/KA)Gαi1. (C) Correlation 
between the ΔMABP and the normalized transduction coefficient for the activation of the GαoA 
pathway, denoted by the Δlog(τ/KA)GαoA. Each point represents the mean ± S.E.M. of the ΔMABP 
in the y-axis and the S.E.M. of the Δlog(τ/KA) in the x-axis. Statistical analyses were performed 
using the Spearman correlation; r coefficient and p values are reported on each graph. 
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Supplementary Table S1. Maximal efficacy (Emax) values of each compound on Gαi/o, cAMP 
inhibition, and β-arrestin recruitment. Each value represents the mean of three independent 
experiments, which were each done in triplicate, and is expressed as the mean ± S.E.M. 
 
analog cAMPi
a 
Emax (%) 
Gαi1 
Emax (%) 
GαoA 
Emax (%) 
β-arrestin 1 
Emax (%) 
β-arrestin 2 
Emax (%) 
1 100.0 ± 1.42 100.0 ± 3.8 100.0 ± 1.9 100.0 ± 2.7 100.0 ± 3.5 
2 83.7 ± 3.0 96.3 ± 7.2 104.4 ± 6.1 91.8 ± 3.9 84.6 ± 2.4 
3 105.1 ± 7.7 98.0 ± 7.5 111.6 ± 8.6 98.2 ± 2.9 102.6 ± 4.9 
4 91.7 ± 4.4 112.2 ± 6.6 108.9 ± 6.2 95.7 ± 4.3 99.2 ± 2.2 
5 92.0 ± 3.5 106.0 ± 6.5 99.1 ± 4.6 108.8 ± 2.5 92.9 ± 2.3 
6 108 ± 3.9 99.7 ± 4.6 95.6 ± 5.1 105.1 ± 3.5 93.1 ± 2.4 
7 84.7 ± 9.9 101.2 ± 5.8 106.6 ± 7.0 105.6 ± 4.3 76.0 ± 3.6 
8 89.9 ± 2.1 95.3 ± 5.9 100.3 ± 6.1 107.5 ± 3.7 92.9 ± 2.5 
9 97.2 ± 2.3 102.4 ± 7.4 111.8 ± 5.2 97.8 ± 4.7 88.0 ± 3.3 
10 101.7 ± 3.7 105.4 ± 5.5 104.2 ± 10.3 48.43 ± 13.7 47.6 ± 9.7 
acAMPi refers to the inhibition of the forskolin-induced cAMP production. 
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Supplementary Table S2. Transduction coefficient (log(τ/KA)) values of each compound on 
Gαi/o, cAMP inhibition, and β-arrestin recruitment. Each value represents the mean of three 
independent experiments, which were each done in triplicate, and is expressed as the mean ± 
S.E.M. 
 
analog 
cAMPia Gαi1 GαoA β-arrestin-1 β-arrestin-2 
log(τ/KA) log(τ/KA) log(τ/KA) log(τ/KA) log(τ/KA) 
1 8.77 ± 0.05 9.05 ± 0.15 7.98 ± 0.19 7.54 ± 0.05 7.51 ± 0.10 
2 8.16 ± 0.10 8.46 ± 0.19 8.99 ± 0.18 6.93 ± 0.06 6.77 ± 0.13 
3 9.45 ± 0.10 8.90 ± 0.17 9.08 ± 0.17 8.49 ± 0.05 8.02 ± 0.08 
4 8.82 ± 0.13 8.60 ± 0.16 8.30 ± 0.17 6.96 ± 0.06 6.90 ± 0.14 
5 9.22 ± 0.10 8.91 ± 0.16 8.89 ± 0.18 8.11 ± 0.04 7.89 ± 0.10 
6 10.48 ± 0.08 8.96 ± 0.16 8.60 ± 0.19 7.83 ± 0.04 7.42 ± 0.12 
7 6.68 ± 0.13 8.19 ± 0.18 8.36 ± 0.18 6.89 ± 0.05 6.43 ± 0.14 
8 10.14 ± 0.10 8.43 ± 0.20 8.44 ± 0.18 8.45 ± 0.05 8.09 ± 0.10 
9 8.45 ± 0.10 8.18 ± 0.17 8.03 ± 0.17 6.96 ± 0.06 6.89 ± 0.12 
10 7.91 ± 0.09 8.51 ± 0.25 9.62 ± 0.19 6.30 ± 0.16 6.48 ± 0.25 
acAMPi refers to the inhibition of the forskolin-induced cAMP production. 
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Supplementary Table S3. Normalized transduction coefficient (Δlog(τ/KA)) values and adjusted p value for each compound on 
Gαi/o, cAMP inhibition, and β-arrestin recruitment. Δlog(τ/KA) values are expressed as the mean ± S.E.M. Adjusted p values result 
from the statistical comparison of the Δlog(τ/KA) on each pathway with a Kruskal-Wallis followed by a Dunn’s post hoc test. An 
adjusted p < 0.05 was considered significant. Shaded boxes represent significantly different values compared to apelin-13. 
analog 
cAMPia Gαi1 GαoA β-arrestin-1 β-arrestin-2 
Δlog(τ/KA) 
Adjusted 
p value Δlog(τ/KA) 
Adjusted 
p value Δlog(τ/KA) 
Adjusted 
p value Δlog(τ/KA) 
Adjusted 
p value Δlog(τ/KA) 
Adjusted 
p value 
1 0.00 ± 0.07 - 0.00 ± 0.22 - 0.00 ± 0.26 - 0.00 ± 0.07 - 0.00 ± 0.14 - 
2 -0.61 ± 0.11 0.0002 -0.60 ± 0.25 0.3146 1.01 ± 0.26 0.0349 -0.60 ± 0.08 0.0001 -0.74 ± 0.16 0.0072 
3 0.68 ± 0.11 0.0001 -0.16 ± 0.24 0.9972 1.09 ± 0.26 0.0187 0.95 ± 0.07 0.0001 0.51 ± 0.13 0.1251 
4 0.05 ± 0.14 0.9994 -0.45 ± 0.23 0.6345 0.32 ± 0.25 0.9410 -0.57 ± 0.07 0.0001 -0.61 ± 0.18 0.0408 
5 0.45 ± 0.11 0.0098 -0.14 ± 0.22 0.9993 0.91 ± 0.26 0.0722 0.57 ± 0.06 0.0001 0.38 ± 0.14 0.3960 
6 1.71 ± 0.09 0.0001 -0.09 ± 0.22 0.9996 0.62 ± 0.27 0.3877 0.30 ± 0.06 0.0521 -0.09 ± 0.15 0.9994 
7 -2.09 ± 0.14 0.0001 -0.86 ± 0.24 0.0536 0.38 ± 0.26 0.8633 -0.64 ± 0.07 0.0001 -1.08 ± 0.17 0.0001 
8 1.37 ± 0.12 0.0001 -0.62 ± 0.25 0.2810 0.46 ± 0.26 0.7133 0.91 ± 0.07 0.0001 0.57 ± 0.14 0.0653 
9 -0.32 ± 0.11 0.1246 -0.87 ± 0.23 0.0495 0.04 ± 0.25 0.9999 -0.58 ± 0.07 0.0001 -0.62 ± 0.15 0.0361 
10 -0.86 ± 0.10 0.0001 -0.54 ± 0.29 0.4302 1.64 ± 0.26 0.0001 -1.23 ± 0.17 0.0001 -1.03 ± 0.27 0.0001 
acAMPi refers to the inhibition of the forskolin-induced cAMP production.  
